Citations (126)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Yue-Ting Chen, Chen-Yu Wang, Yi-Wei Yin, Zi-Ran Li, Wei-Wei Lin, Min Zhu & Zheng Jiao. (2021) Population pharmacokinetics of oxcarbazepine: a systematic review. Expert Review of Clinical Pharmacology 14:7, pages 853-864.
Read now
Read now
Ricardo Blanco-Castañeda, Carlos Galaviz-Hernández, Paula C. S. Souto, Victor Vitorino Lima, Fernanda R. Giachini, Carlos Escudero, Alicia E Damiano, L. Jazel Barragán-Zúñiga, Gerardo Martínez-Aguilar & Martha Sosa-Macías. (2020) The role of xenobiotic-metabolizing enzymes in the placenta: a growing research field. Expert Review of Clinical Pharmacology 13:3, pages 247-263.
Read now
Read now
Alberto Verrotti, Giulia Iapadre, Giulia Di Donato, Ludovica Di Francesco, Luca Zagaroli, Sara Matricardi, Vincenzo Belcastro & Maria Laura Iezzi. (2019) Pharmacokinetic considerations for anti-epileptic drugs in children. Expert Opinion on Drug Metabolism & Toxicology 15:3, pages 199-211.
Read now
Read now
Petra Malátková & Vladimír Wsól. (2014) Carbonyl reduction pathways in drug metabolism. Drug Metabolism Reviews 46:1, pages 96-123.
Read now
Read now
Peter Stopfer, Karin Rathgen, Daniel Bischoff, Silke Lüdtke, Kristell Marzin, Rolf Kaiser, Klaus Wagner & Thomas Ebner. (2011) Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 41:4, pages 297-311.
Read now
Read now
Bernhard J Steinhoff. (2009) Oxcarbazepine extended-release formulation in epilepsy. Expert Review of Clinical Pharmacology 2:2, pages 155-162.
Read now
Read now
Shufeng Zhou, Eli Chan, Wei Duan, Min Huang & Yu-Zong Chen. (2005) Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance. Drug Metabolism Reviews 37:1, pages 41-213.
Read now
Read now
Paul Whiteley & Paul Shattock MRPharmS. (2003) What Makes Trans‐indolyl‐3‐acryloylglycine Identified by High‐performance Liquid Chromatography Relevant to Pervasive Developmental Disorders?. Journal of Nutritional & Environmental Medicine 13:4, pages 231-237.
Read now
Read now
Ahmad Beydoun & Ekrem Kutluay. (2002) Oxcarbazepine. Expert Opinion on Pharmacotherapy 3:1, pages 59-71.
Read now
Read now
Steven C Schachter. (1999) Oxcarbazepine: current status and clinical applications. Expert Opinion on Investigational Drugs 8:7, pages 1103-1112.
Read now
Read now
J. Wagner & K. Schmid. (1987) Induction of microsomal enzymes in rat liver by oxcarbazepine, 10,11-dihydro-10-hydroxy-carbamazepine and carbamazepine. Xenobiotica 17:8, pages 951-956.
Read now
Read now
Articles from other publishers (115)
A. V. Pirogov, N. A. Gandlevskii, A. A. Vasil’eva, S. S. Barsegyan & A. E. Nosyrev. (2023) Highly Sensitive Determination of Carbamazepine and Oxcarbazepine and Identification of Their Degradation Products in Material Evidences and Human Cadaveric Liver by Gas Chromatography–Mass Spectrometry. Journal of Analytical Chemistry 78:6, pages 783-793.
Crossref
Crossref
Jaydeep Sinha, Eleni Karatza & Daniel Gonzalez. (2021) Physiologically‐based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents. CPT: Pharmacometrics & Systems Pharmacology 11:2, pages 225-239.
Crossref
Crossref
Karthik Rajendran, Bhadram Kalyan Chekraverthy, Rajendran Sankham Devendran, R Jasmin Sajini & Krishnaveni Nagappan. (2021) Simultaneous quantification of oxcarbazepine and its active metabolite in spiked human plasma using ultra performance liquid chromatography–MS/MS. Bioanalysis 13:16, pages 1259-1273.
Crossref
Crossref
Yoonhyuk Jang, Seonghae Yoon, Tae-Joon Kim, SeungHwan Lee, Kyung-Sang Yu, In-Jin Jang, Kon Chu & Sang Kun Lee. (2021) Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. Scientific Reports 11:1.
Crossref
Crossref
Kai Huang, Linling Que, Ying Ding, Nannan Chu, Zhenzhong Qian, Wei Qin, Yuanxing Chen, Jisheng Zhang & Qing He. (2021) Identification of human uridine diphosphate-glucuronosyltransferase isoforms responsible for the glucuronidation of 10,11-dihydro-10-hydroxy-carbazepine. Journal of Pharmacy and Pharmacology 73:3, pages 388-397.
Crossref
Crossref
Shristy S. Tiwari, Vivek Dhiman, Sumit Mukesh, Abhay T. Sangamwar, Ragampeta Srinivas & M.V.N. Kumar Talluri. (2020)
Identification and characterization of novel metabolites of nintedanib by ultra‐performance liquid chromatography/quadrupole time‐of‐flight tandem mass spectrometry with
in silico
toxicological assessment
. Rapid Communications in Mass Spectrometry 34:22.
Crossref
Crossref
Rodrigo Rocamora, Jukka Peltola, Giovanni Assenza, Rob McMurray & Vicente Villanueva. (2020) Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice. Seizure 75, pages 121-128.
Crossref
Crossref
Chao-Yang Chen, Ying Zhou, Yi-Min Cui, Ting Yang, Xia Zhao & Ye Wu. (2019) Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. Journal of Clinical Pharmacy and Therapeutics 44:2, pages 300-311.
Crossref
Crossref
Christelle Rodrigues, Catherine Chiron, Elisabeth Rey, Olivier Dulac, Emmanuelle Comets, Gérard Pons & Vincent Jullien. (2017) Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. British Journal of Clinical Pharmacology 83:12, pages 2695-2708.
Crossref
Crossref
Natalicia de Jesus Antunes, Sven C. van Dijkman, Vera Lucia Lanchote, Lauro Wichert-Ana, Eduardo Barbosa Coelho, Veriano Alexandre Junior, Osvaldo Massaiti Takayanagui, Eduardo Tozatto, J.G. Coen van Hasselt & Oscar Della Pasqua. (2017) Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. European Journal of Pharmaceutical Sciences 109, pages S116-S123.
Crossref
Crossref
Shuai Yu, Feng Li & Sanghee Kim. (2017)
(
E
)- and (
Z
)-Stereodefined Enol Sulfate Esters Derived from α-Aryl Aldehydes: Stereocomplementary Synthesis of Styryl Sulfate Natural Products
. The Journal of Organic Chemistry 82:13, pages 6992-6999.
Crossref
Crossref
E. Schmid, G. Kuchukhidze, M. Kirschner, M. Leitinger, J. Höfler, A. Rohracher, G. Kalss, A.-S. Wendling, B. J. Steinhoff & E. Trinka. (2017) Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study. Acta Neurologica Scandinavica 135:4, pages 449-453.
Crossref
Crossref
Petra Malátková, Matthildi Kanavi, Milan Nobilis & Vladimír Wsól. (2016) In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chemico-Biological Interactions 258, pages 153-158.
Crossref
Crossref
Hueng-Chuen Fan, Herng-Shen Lee, Kai-Ping Chang, Yi-Yen Lee, Hsin-Chuan Lai, Pi-Lien Hung, Hsiu-Fen Lee & Ching-Shiang Chi. (2016) The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism. International Journal of Molecular Sciences 17:8, pages 1242.
Crossref
Crossref
Zhichao Yang, Xueyu Xu, Lingxia Sun, Xue Zhao, Hao Wang, John Paul Fawcett, Yan Yang & Jingkai Gu. (2016) Development and validation of an enantioselective SFC-MS/MS method for simultaneous separation and quantification of oxcarbazepine and its chiral metabolites in beagle dog plasma. Journal of Chromatography B 1020, pages 36-42.
Crossref
Crossref
Ali Sigaroudi, Gerd A. Kullak-Ublick & Stefan Weiler. (2015) Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine. European Journal of Clinical Pharmacology 72:3, pages 377-378.
Crossref
Crossref
Natalícia de Jesus Antunes, Lauro Wichert-Ana, Eduardo Barbosa Coelho, Oscar Della Pasqua, Veriano Alexandre Junior, Osvaldo Massaiti Takayanagui, Eduardo Tozatto, Maria Paula Marques & Vera Lucia Lanchote. (2015) Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. European Journal of Clinical Pharmacology 72:2, pages 195-201.
Crossref
Crossref
Robert Gurke, Martin Rößler, Conrad Marx, Sam Diamond, Sara Schubert, Reinhard Oertel & Joachim Fauler. (2015) Occurrence and removal of frequently prescribed pharmaceuticals and corresponding metabolites in wastewater of a sewage treatment plant. Science of The Total Environment 532, pages 762-770.
Crossref
Crossref
Jukka Peltola, Martin Holtkamp, Rodrigo Rocamora, Philippe Ryvlin, Kasia Sieradzan & Vicente Villanueva. (2015) Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate — Expert opinion. Epilepsy & Behavior 50, pages 46-49.
Crossref
Crossref
Eleni N. Evgenidou, Ioannis K. Konstantinou & Dimitra A. Lambropoulou. (2015) Occurrence and removal of transformation products of PPCPs and illicit drugs in wastewaters: A review. Science of The Total Environment 505, pages 905-926.
Crossref
Crossref
Germán Sierra-Paredes, Ana I Loureiro, Lyndon C Wright, Germán Sierra-Marcuño & Patrício Soares-da-Silva. (2014) Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. BMC Neuroscience 15:1.
Crossref
Crossref
Yang Wang, Hua-nian Zhang, Chang-he Niu, Ping Gao, Yu-jun Chen, Jing Peng, Mao-chang Liu & Hua Xu. (2014) Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacologica Sinica 35:10, pages 1342-1350.
Crossref
Crossref
Petra Malátková, Lucie Havlíková & Vladimír Wsól. (2014) The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chemico-Biological Interactions 220, pages 241-247.
Crossref
Crossref
Hélène Fenet, Lauren Arpin-Pont, Alice Vanhoutte-Brunier, Dominique Munaron, Annie Fiandrino, Maria-Jesus Martínez Bueno, Clotilde Boillot, Claude Casellas, Olivier Mathieu & Elena Gomez. (2014) Reducing PEC uncertainty in coastal zones: A case study on carbamazepine, oxcarbazepine and their metabolites. Environment International 68, pages 177-184.
Crossref
Crossref
Arnold Bahlmann, Werner Brack, Rudolf J. Schneider & Martin Krauss. (2014) Carbamazepine and its metabolites in wastewater: Analytical pitfalls and occurrence in Germany and Portugal. Water Research 57, pages 104-114.
Crossref
Crossref
Heidrun Potschka, Jonna Soerensen, Anton Pekcec, Ana Loureiro & Patrício Soares-da-Silva. (2014) Effect of eslicarbazepine acetate in the corneal kindling progression and the amygdala kindling model of temporal lobe epilepsy. Epilepsy Research 108:2, pages 212-222.
Crossref
Crossref
Ana Fortuna, Gilberto Alves & Amílcar Falcão. (2013) Chiral chromatographic resolution of antiepileptic drugs and their metabolites: a challenge from the optimization to the application. Biomedical Chromatography 28:1, pages 27-58.
Crossref
Crossref
Natalicia de Jesus Antunes, Lauro Wichert-Ana, Eduardo Barbosa Coelho, Oscar Della Pasqua, Veriano AlexandreJr.Jr., Osvaldo Massaiti Takayanagui, Eduardo Tozatto & Vera Lucia Lanchote. (2013) Analysis of Oxcarbazepine and the 10-Hydroxycarbazepine Enantiomers in Plasma by LC-MS/MS: Application in a Pharmacokinetic Study. Chirality 25:12, pages 897-903.
Crossref
Crossref
Luca Vaghi, Emanuela Gaudino, Giancarlo Cravotto, Giovanni Palmisano & Andrea Penoni. (2013) A Structurally Diverse Heterocyclic Library by Decoration of Oxcarbazepine Scaffold. Molecules 18:11, pages 13705-13722.
Crossref
Crossref
Qin Wang. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
3
.
Meir Bialer. (2012) Chemical properties of antiepileptic drugs (AEDs). Advanced Drug Delivery Reviews 64:10, pages 887-895.
Crossref
Crossref
Cecilie Johannessen Landmark, Svein I. Johannessen & Torbjörn Tomson. (2012) Host factors affecting antiepileptic drug delivery—Pharmacokinetic variability. Advanced Drug Delivery Reviews 64:10, pages 896-910.
Crossref
Crossref
Meir Bialer & Patricio Soares‐da‐Silva. (2012) Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 53:6, pages 935-946.
Crossref
Crossref
Dave Berry. 2012. Neurology and Pregnancy. Neurology and Pregnancy
27
33
.
Jeannine M. Conway, Ilo E. Leppik & Angela K. Birnbaum. 2012. Swaiman's Pediatric Neurology. Swaiman's Pediatric Neurology
811
835
.
Mitesh Bhatt, Sanjay Shah & Shivprakash. (2011) Rapid ultraperformance liquid chromatography-tandem mass spectrometry method for quantification of oxcarbazepine and its metabolite in human plasma. Biomedical Chromatography 25:7, pages 751-759.
Crossref
Crossref
G. Flesch, C. Czendlik, D. Renard & P. Lloyd. (2011) Pharmacokinetics of the Monohydroxy Derivative of Oxcarbazepine and Its Enantiomers after a Single Intravenous Dose Given as Racemate Compared with a Single Oral Dose of Oxcarbazepine. Drug Metabolism and Disposition 39:6, pages 1103-1110.
Crossref
Crossref
B.J. Steinhoff, E. Trinka & A.S. Wendling. (2010) Abrupter Austausch von retardiertem Oxcarbazepin gegen EslicarbazepinacetatAbrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate. Der Nervenarzt 82:6, pages 764-767.
Crossref
Crossref
Catherine Dicaire, Eugénie-Raphaelle Bérubé, Isabelle Dumont, Milton Furtado & Fabio Garofolo. (2011) Impact of oxcarbazepine sulfate metabolite on incurred sample reanalysis and quantification of oxcarbazepine. Bioanalysis 3:9, pages 973-982.
Crossref
Crossref
Ana Fortuna, Joana Sousa, Gilberto Alves, Amílcar Falcão & Patrício Soares-da-Silva. (2010) Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Analytical and Bioanalytical Chemistry 397:4, pages 1605-1615.
Crossref
Crossref
Amy S. Wasterlain & Nitin K. Sethi. 2010. Atlas of Epilepsies. Atlas of Epilepsies
1797
1806
.
Marie Leclercq, Olivier Mathieu, Elena Gomez, Claude Casellas, Hélène Fenet & Dominique Hillaire-Buys. (2008) Presence and Fate of Carbamazepine, Oxcarbazepine, and Seven of Their Metabolites at Wastewater Treatment Plants. Archives of Environmental Contamination and Toxicology 56:3, pages 408-415.
Crossref
Crossref
Bernhard J Steinhoff. (2009) Verzögert freigesetztes Oxcarbazepin – Überblick und klinische ErfahrungenModified-release (MR) oxcarbazepine – overview and clinical experiences. Zeitschrift für Epileptologie 22:1, pages 2-8.
Crossref
Crossref
Thomas Zheng, Alison L. Clarke, Margaret J. Morris, Christopher A. Reid, Steven Petrou & Terence J. O'Brien. (2009)
Oxcarbazepine, not its active metabolite, potentiates GABA
A
activation and aggravates absence seizures
. Epilepsia 50:1, pages 83-87.
Crossref
Crossref
Scott Mintzer. 2009. Pharmacology and Therapeutics. Pharmacology and Therapeutics
663
683
.
Philip N. Patsalos, David J. Berry, Blaise F. D. Bourgeois, James C. Cloyd, Tracy A. Glauser, Svein I. Johannessen, Ilo E. Leppik, Torbjrn Tomson & Emilio Perucca. (2008) Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:7, pages 1239-1276.
Crossref
Crossref
Ulrich C. Lutz, Gerlinde Wiatr, Hans-Jorg Gaertner & Mathias Bartels. (2007) Oxcarbazepine Treatment During Breast-Feeding. Journal of Clinical Psychopharmacology 27:6, pages 730-732.
Crossref
Crossref
Maria Bernadete de Sousa Maia, Demétrius Fernandes do Nascimento, Ismael Leite Martins, Adriano Nunes Cunha, Francisco Evanir Gonçalves de Lima, Fernando Antônio Frota Bezerra, Manoel Odorico de Moraes & Maria Elisabete Amaral de Moraes. (2007) Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography–electrospray tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 45:2, pages 304-311.
Crossref
Crossref
Anna Maria Mauro, Chiara Bomprezzi, Simonetta Morresi, Leandro Provinciali, Francesco Formica, Maurizio Iacoangeli & Massimo Scerrati. (2006) Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. Journal of Neuro-Oncology 81:3, pages 279-285.
Crossref
Crossref
Jakob ChristensenAnne SabersPer Sidenius. (2006) Oxcarbazepine concentrations during pregnancy: A retrospective study in patients with epilepsy. Neurology 67:8, pages 1497-1499.
Crossref
Crossref
Luis Almeida, Amílcar Falcão, Joana Maia, Dago Mazur, Manfred Gellert & Patrício Soares-da-Silva. (2005) Single-Dose and Steady-State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093) in Healthy Elderly and Young Subjects. The Journal of Clinical Pharmacology 45:9, pages 1062-1066.
Crossref
Crossref
Jarogniew J. Luszczki, Marta M. Andres & Stanislaw J. Czuczwar. (2005) Synergistic interaction of gabapentin and oxcarbazepine in the mouse maximal electroshock seizure model—an isobolographic analysis. European Journal of Pharmacology 515:1-3, pages 54-61.
Crossref
Crossref
Vincenzo Pucci & Maria Augusta Raggi. (2005) Analysis of antiepileptic drugs in biological fluids by means of electrokinetic chromatography. ELECTROPHORESIS 26:4-5, pages 767-782.
Crossref
Crossref
Elisabeth Rey, Christine Bulteau, Jacques Motte, Agnes Tran, Yvonne Sturm, Joseph D'Souza, Sabri Markabi, Gérard Pons & Olivier Dulac. (2004) Oxcarbazepine Pharmacokinetics and Tolerability in Children With Inadequately Controlled Epilepsy. The Journal of Clinical Pharmacology 44:11, pages 1290-1300.
Crossref
Crossref
Dieter Schmidt & Christian E. Elger. (2004) What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?. Epilepsy & Behavior 5:5, pages 627-635.
Crossref
Crossref
Luis Almeida & Patrício Soares-da-Silva. (2004) Safety, Tolerability, and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic, in a Rising Multiple-Dose Study in Young Healthy Humans. The Journal of Clinical Pharmacology 44:8, pages 906-918.
Crossref
Crossref
Ricardo Meischenguiser, Carlos H. D'Giano & Stella M. Ferraro. (2004) Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy & Behavior 5:2, pages 163-167.
Crossref
Crossref
G??rard Flesch. (2004) Overview of the Clinical Pharmacokinetics of Oxcarbazepine. Clinical Drug Investigation 24:4, pages 185-203.
Crossref
Crossref
E. Faught. 2004. The Treatment of Epilepsy. The Treatment of Epilepsy
451
460
.
Svein I. Johannessen, Dina Battino, David J. Berry, Meir Bialer, Günter Krämer, Torbjörn Tomson & Philip N. Patsalos. (2003) Therapeutic Drug Monitoring of the Newer Antiepileptic Drugs. Therapeutic Drug Monitoring 25:3, pages 347-363.
Crossref
Crossref
Vincenzo Pucci, Ernst Kenndler & Maria Augusta Raggi. (2003) Quantitation of oxcarbazepine and its metabolites in human plasma by micellar electrokinetic chromatography. Biomedical Chromatography 17:4, pages 231-238.
Crossref
Crossref
Jarogniew J. Luszczki, Kinga K. Borowicz, Mariusz Swiader & Stanislaw J. Czuczwar. (2003) Interactions Between Oxcarbazepine and Conventional Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis. Epilepsia 44:4, pages 489-499.
Crossref
Crossref
Ekrem Kutluay, Kevin McCague, Joseph D’Souza & Ahmad Beydoun. (2003) Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy & Behavior 4:2, pages 175-180.
Crossref
Crossref
Donald J. AbrahamKenneth R. Scott. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
263
328
.
Luis Almeida & Patr??cio Soares-da-Silva. (2003) Safety, Tolerability and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic Agent, during First Administration to Humans. Drugs in R & D 4:5, pages 269-284.
Crossref
Crossref
Theodor W May, Elisabeth Korn-Merker & Bernhard Rambeck. (2003) Clinical Pharmacokinetics of Oxcarbazepine. Clinical Pharmacokinetics 42:12, pages 1023-1042.
Crossref
Crossref
Tracy A. Glauser. (2001) Oxcarbazepine in the Treatment of Epilepsy. Pharmacotherapy 21:8, pages 904-919.
Crossref
Crossref
Dominik Hainzl, António Parada & Patrı́cio Soares-da-Silva. (2001) Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(−)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Research 44:2-3, pages 197-206.
Crossref
Crossref
Steven C. Schachter. (2001) Epilepsy. Neurologic Clinics 19:1, pages 57-78.
Crossref
Crossref
Dieter Schmidt & Rajesh Sachdeo. (2000) Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use. Epilepsy & Behavior 1:6, pages 396-405.
Crossref
Crossref
Steven C. Schachter. (2000) The Next Wave of Anticonvulsants. CNS Drugs 14:3, pages 229-249.
Crossref
Crossref
James C. Cloyd & Rory P. Remmel. (2012) Antiepileptic Drug Pharmacokinetics and Interactions: Impact on Treatment of Epilepsy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 20:8P2.
Crossref
Crossref
A. BeydounR.C. SachdeoW.E. RosenfeldG.L. KraussN. SesslerP. MesenbrinkL. KramerJ. D’Souza. (2000) Oxcarbazepine monotherapy for partial-onset seizures. Neurology 54:12, pages 2245-2251.
Crossref
Crossref
Simon Shorvon. (2000) Oxcarbazepine: a review. Seizure 9:2, pages 75-79.
Crossref
Crossref
Andrew Volosov, Meir Bialer, Sun Xiaodong, Emilio Perucca, Amnon Sintov & Boris Yagen. (2000) Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine. Journal of Chromatography B: Biomedical Sciences and Applications 738:2, pages 419-425.
Crossref
Crossref
John M. Pellock & Lawrence D. Morton. (2000) Treatment of epilepsy in the multiply handicapped. Mental Retardation and Developmental Disabilities Research Reviews 6:4, pages 309-323.
Crossref
Crossref
Jan Benes, António Parada, Anabela A. Figueiredo, Paula C. Alves, Ana P. Freitas, David A. Learmonth, Rodrigo A. Cunha, José Garrett & Patrício Soares-da-Silva. (1999)
Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5
H
-dibenz[
b
,
f
]azepine-5-carboxamide Derivatives
. Journal of Medicinal Chemistry 42:14, pages 2582-2587.
Crossref
Crossref
Andrew Volosov, Amnon Sintov & Meir Bialer. (1999) Stereoselective Pharmacokinetic Analysis of the Antiepileptic 10-Hydroxycarbazepine in Dogs. Therapeutic Drug Monitoring 21:2, pages 219-223.
Crossref
Crossref
P Myllynen, P Pienimäki, H Raunio & K Vähäkangas. (2016) Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. Human & Experimental Toxicology 17:12, pages 668-676.
Crossref
Crossref
P. Pienimäki, E. Lampela, J. Hakkola, P. Arvela, H. Raunio & K. Vähäkangas. (2005) Pharmacokinetics of Oxcarbazepine and Carbamazepine in Human Placenta. Epilepsia 38:3, pages 309-316.
Crossref
Crossref
S. I. Johannessen. (1997) Pharmacokinetics and Interaction Profile of Topiramate: Review and Comparison with Other Newer Antiepileptic Drugs. Epilepsia 38:s1, pages S18-S23.
Crossref
Crossref
Lennart Gram. (1996) Pharmacokinetics of New Antiepileptic Drugs. Epilepsia 37:s6, pages S12-S16.
Crossref
Crossref
Emilio Perucca. (1996) Pharmacokinetic Profile of Topiramate in Comparison with Other New Antiepileptic Drugs. Epilepsia 37:s2, pages S8-S13.
Crossref
Crossref
Katariina Castrén, Päivi Pienimäki, Pentti Arvela & Kirsi Vähäkangas. (2016) Metabolites and DNA-binding of carbamazepine and oxcarbazepine in vitro by rat liver microsomes. Human & Experimental Toxicology 15:7, pages 577-582.
Crossref
Crossref
J.W. Britton & E.L. So. (1995) New antiepileptic drugs: Prospects for the future. Journal of Epilepsy 8:4, pages 267-281.
Crossref
Crossref
P. Pienimäki, S. Fuchs, J. Isojärvi & K. Vähäkangas. (1995) Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 673:1, pages 97-105.
Crossref
Crossref
K. M. Matar, P. J. Nicholls, M. I. Al–Hassan & A. Tekle. (1995) Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high–performance liquid chromatography. Journal of Clinical Pharmacy and Therapeutics 20:4, pages 229-234.
Crossref
Crossref
P. Pienimäki, A.‐L. Hartikainen, P. Arvela, T. Partanen, R. Herva, O. Pelkonen & K. Vähäkangas. (2005) Carbamazepine and Its Metabolites in Human Perfused Placenta and in Maternal and Cord Blood. Epilepsia 36:3, pages 241-248.
Crossref
Crossref
A. Sabers & L. Gram. (2011) Progress in the medical treatment of epilepsy: an overview of new antiepileptic drugs. European Journal of Neurology 1:3, pages 189-202.
Crossref
Crossref
M.C. Walker & P.N. Patsalos. (1995) Clinical pharmacokinetics of new antiepileptic drugs. Pharmacology & Therapeutics 67:3, pages 351-384.
Crossref
Crossref
George deStevens, V. Zingel, C. Leschke, W. Schunack, Paul D. Hoeprich, Richard M. Schultz, P. K. Mehrotra, Sanjay Batra, A. P. Bhaduri, Anil K. Saxena & Mridula SaxenaAnil K. Saxena & Mridula Saxena. 1995. Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques
185
291
.
Artur W. Wamil, Markus Schmutz, Chantal Portet, Karl F. Feldmann & Michael J. McLean. (1994) Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. European Journal of Pharmacology 271:2-3, pages 301-308.
Crossref
Crossref
M. Schmutz, F. Brugger, C. Gentsch, M. J. McLean & H. R. Olpe. (1994) Oxcarbazepine: Preclinical Anticonvulsant Profile and Putative Mechanisms of Action. Epilepsia 35:s5, pages S47-S50.
Crossref
Crossref
M.C. Rouan, M. Decherf, V. Le Clanche, J.B. Lecaillon & J. Godbillon. (1994) Automated microanalysis of oxcarbazepine and its monohydroxy and transdiol metabolites in plasma by liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 658:1, pages 167-172.
Crossref
Crossref
M. J. McLean, M. Schmutz, A. W. Wamil, H.-R. Olpe, C. Portet & K. F. Feldmann. (1994) Oxcarbazepine: Mechanisms of Action. Epilepsia 35:s3, pages S5-S9.
Crossref
Crossref
P. Lloyd, G. Flesch & W. Dieterle. (1994) Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine. Epilepsia 35:s3, pages S10-S13.
Crossref
Crossref
PJ McKee, J Blacklaw, G Forrest, RA Gillham, SM Walker, D Connelly & MJ Brodie. (2012) A double‐blind, placebo‐controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.. British Journal of Clinical Pharmacology 37:1, pages 27-32.
Crossref
Crossref
Roger J. Porter. (2008) New Developments in the Search for Improved Antiepileptic Drugs. Psychiatry and Clinical Neurosciences 47:2, pages 145-162.
Crossref
Crossref
Y. A. Hekster, D. J. P. Wijsman, E. W. Wuis, T. B. Vree & H. Meinardi. 1993. Quantitative Assessment in Epilepsy Care. Quantitative Assessment in Epilepsy Care
109
116
.
G. Kramer, B. Tettenborn, P. Klosterskov Jensen, G. P. Menge & K. D. Stoll. (1992) Oxcarbazepine Does Not Affect the Anticoagulant Activity of Warfarin. Epilepsia 33:6, pages 1145-1148.
Crossref
Crossref
T. Keränen, J. Jolkkonen, P. K. Jensen, G. P. Menge & P. Andersson. (1992) Absence of interaction between oxcarbazepine and erythromycin. Acta Neurologica Scandinavica 86:2, pages 120-123.
Crossref
Crossref
T. Keränen, J. Jolkkonen, P. Klosterskov-Jensen & G. P. Menge. (2009) Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurologica Scandinavica 85:4, pages 239-242.
Crossref
Crossref
P. H. Mogensen, L. Jórgensen, J. Boas, M. Dam, A. Vesterager, G. Flesch & P. K. Jensen. (2009) Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites. Acta Neurologica Scandinavica 85:1, pages 14-17.
Crossref
Crossref
R. Hartley, M. Green, M. D. Lucock, S. Ryan & W. I. Forsythe. (1991) Solid phase extraction of oxcarbazepine and its metabolites from plasma for analysis by high performance liquid chromatography. Biomedical Chromatography 5:5, pages 212-215.
Crossref
Crossref
JG Larkin, PJ McKee, G Forrest, GH Beastall, BK Park, JI Lowrie, P Lloyd & MJ Brodie. (2012) Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.. British Journal of Clinical Pharmacology 31:1, pages 65-71.
Crossref
Crossref
A. Kumps & C. Wurth. (2006) Oxcarbazepine disposition: Preliminary observations in patients. Biopharmaceutics & Drug Disposition 11:4, pages 365-370.
Crossref
Crossref
A.A. Elyas, V.D. Goldberg & P.N. Patsalos. (1990) Simple and rapid micro-analytical high-performance liquid chromatographic technique for the assay of oxcarbazepine and its primary active metabolite 10-hydroxycarbazepine. Journal of Chromatography B: Biomedical Sciences and Applications 528, pages 473-479.
Crossref
Crossref
S.C. Pendlebury, D.K. Moses & M.J. Eadie. (2016) Hyponatraemia during Oxcarbazepine Therapy. Human Toxicology 8:5, pages 337-344.
Crossref
Crossref
. (1989) Oxcarbazepine. The Lancet 334:8656, pages 196-198.
Crossref
Crossref
. (1989) Databases for Health Care Outcomes. The Lancet 334:8656, pages 195-196.
Crossref
Crossref
J M Zakrzewska & P N Patsalos. (1989) Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia.. Journal of Neurology, Neurosurgery & Psychiatry 52:4, pages 472-476.
Crossref
Crossref
R. G. Dickinson, W. D. Hooper, P. R. Dunstan & M. J. Eadie. (1989) First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. European Journal of Clinical Pharmacology 37:1, pages 69-74.
Crossref
Crossref
A. L. Burlingame, D. Maltby, D. H. Russell & P. T. Holland. (2002) Mass spectrometry. Analytical Chemistry 60:12, pages 294-342.
Crossref
Crossref
Richard N. Armstrong. 1988.
315
324
.
Roland Heckendorn. (1987) Synthesis oftrans-10,11-Dihydro-10,11-dihydroxy-5H-dibenz[b,f]azepine-5-carboxamide, a Major Metabolite of Carbamazepine. Helvetica Chimica Acta 70:7, pages 1955-1962.
Crossref
Crossref